Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia was written by Abeykoon, Jithma P.;Zanwar, Saurabh;Ansell, Stephen M.;Muchtar, Eli;He, Rong;Greipp, Patricia T.;King, Rebecca L.;Ailawadhi, Sikander;Paludo, Jonas;Larsen, Jeremy T.;Habermann, Thomas M.;Inwards, David;Go, Ronald S.;Thanarajasingam, Gita;Buadi, Francis;Dispenzieri, Angela;Thompson, Carrie A.;Witzig, Thomas E.;Lacy, Martha;Gonsalves, Wilson;Nowakowski, Grzegorz S.;Dingli, David;Rajkumar, Sundararajan Vincent;Kyle, Robert A.;Sher, Taimur;Roy, Vivek;Rosenthal, Allison;Chanan-Khan, Asher A.;Reeder, Craig;Gertz, Morie A.;Kumar, Shaji;Kapoor, Prashant. And the article was included in American Journal of Hematology in 2021.Product Details of 16506-27-7 The following contents are mentioned in the article:
Comparative data guiding initial therapy for Waldenstrom macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab-based frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, rituximab, cyclophosphamide (DRC); and bortezomib, dexamethasone, rituximab (BDR) in 220 treatment-naive patients with WM, seen at Mayo Clinic between Nov. 1, 2000 and Oct. 31, 2019. The median follow-up was 4.5 (95%CI: 4-5) years. The R-Benda cohort (n = 83) demonstrated superior overall response rate (ORR: 98%), in comparison to DRC (n = 92, ORR: 78%) or BDR (n = 45, ORR: 84%) cohorts, p = 0.003. Similarly, longer progression-free survival (PFS) was evident with R-Benda use [median 5.2 vs. 4.3 (DRC) and 1.8 years (BDR), p < 0.001]. The time-to-next therapy (TTNT) favored R-Benda median, not-reached, 4.4 (DRC) and 2.6 years (BDR), p < 0.001. These endpoints were comparable between the DRC and BDR cohorts. Overall survival (OS) was similar across the three cohorts, p = 0.77. In a subset anal. of 142 patients genotyped for MYD88L265P mutation, the ORR, PFS and TTNT were unaffected by the patients’ MYD88 signature within each cohort. In conclusion, ORR, PFS and TTNT with R-Benda are superior compared to DRC or BDR in treatment-naive patients with active WM. The patient outcomes with any one of these three regimens are unaffected by the MYD88L265P mutation status. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Product Details of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem